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ANALYSIS ofthedermatoglyphic features
of 152 children attending the Hospitals
for Sick Children for treatment of acute
lymphoblastic leukaemia (ALL) suggested
that the duration offirst remission in these
patients was inversely related to the
amount of finger-tip pattern as measured
by the number of digital whorls and the
pattern intensity on the fingers (Till et al.,
1978). In order to try to verify this finding
the dermatoglyphic patterns have been
studied in a group of patients with ALL
all ofwhom have survived at least 6 years.
Dermatoglyphic prints were made from
the hands and feet of 123 (65 male, 58
female)patients with ALL who were diag-
nosed before 1 January 1972. Eighty-two
ofthese were survivors from the Concord or
UKALL I Trials (Medical Research Coun-
cil, 1971, 1973) and 41 were from a group
of long-surviving patients collected pre-
viously by personal enquiry among hos-
pitals throughout the United Kingdom
(Till et al., 1973). At the time the dermato-
glyphic prints were taken the 123 patients
had survived between 6 and 24 years
since diagnosis; 83 of them had not re-
lapsed since the induction of their initial
remission. The diagnosis of ALL had been
confirmed by marrow examination in all
the patients. Treatment schedules had
varied considerably; 37 (30%0) patients
received chemotherapy for less than 2
years after diagnosis and a further 13
(11%) received maintenance therapy at
very low dosage. Fifty-eight (47%0) were
given prophylactic therapy to the central
nervous system (CNS) but this was ad-
ministered within 12 months of diagnosis
in only 35.
Mean values for those dermatoglyphic
features which were found previously to
be ofprognostic value (Till et al., 1978) are
shown in the Table; the group of patients
described here is compared with those in
the previous series in which it was found
that the number of digital whorls and the
pattern intensity on the fingers were
inversely related to the length of first
remission. However, these dermatoglyphic
characteristics are very similar in both
series and there is no evidence in the
present series that even those patients who
survived more than 6 years withoutrelapse
have less than normal amounts offinger-tip
pattern. Further subdivision of the long-
surviving patients according to age at
diagnosis, sex, durationofchemotherapyor
use of prophylactic treatment to the CNS
revealednogroupwithadistinctiveamount
of finger-tip pattern.
Dermatoglyphic features in the long-
surviving series are similar to those in the
control group in the earlier series, and this
supports the conclusion reached pre-
viously that the dermatoglyphics of ALL
patients do not differ significantly from
those of controls (Till et al., 1978). The
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TABLE.-Comparison of dermatoglyphic features in ALL patients according to response
to treatment
Mean Mean No. with
total Mean no. pattern hypothenar No. with
No. of ridge digital intensity loop H hypothenar
Patients patients count whorls fingers (%) loop H!
Previous series (Till et al., 1978)
Whole group M 87 132 2-87 12-3 27 (31%) 0
F 65 134 2-25 12-0 22 (34%) 1
Depth or Relapse within 2 M 26 143 3-65 13-1 10 (38%) 0
yrs of diagnosis F 9 140 3-56 13-0 2 (22%) 0
Survived 2yrs without M 34 115 1-97 11-2 11 (32%) 0
relapse F 38 136 2-32 12-1 15 (39%) 1
Present series (long-term survivors)
Whole group M 65 131 2-83 12-3 21 (32%) 1
F 58 136 2-76 12-5 31 (55%) 5
Patients still in first M 42 130 2-81 12-1 16 (38%) 1
remission F 41 136 2-90 12-6 20 (49%) 2
lack of agreement between the findings in
the long-surviving group and the subgroup
previously described, who survived at
least 2 years without relapse, suggests
either that the previous findings occurred
by chance or that factors distinguishing
very long survivors are independent
of those which determine good initial
response amongst unselected patients.
This latter explanation seems unlikely,
particularly as the differences in relapse
rates noted when the previous series was
subdivided according to dermatoglyphic
features have tended to diminish after
follow-up for a further 18 months.
Significantly more (P < 0.05) females in
the long-surviving group than in the
previous group bore hypothenar loop H,
but there was no marked difference
among the males (Table). It is of interest
that amongst the long-term survivors
with hypothenar loop H, 6 (4.9% of all
patients) had this in the form H! compared
with only 1 (0 7%) in the earlier series.
This loop was not found among 295
members of control families in the earlier
series (Till et al., 1978) and has been re-
ported to occur in less than 1% ofcontrols
(Weninger, 1947). The prevalence of the
loop was found recently (Till et al., 1978)
to be significantly increased within fami-
lies of patients with acute myeloblastic
leukaemia (AML).
In both ALL and AML patients this
finding was apparently associated with a
good prognosis. Of the 3 patients pre-
viously described as bearing this loop
(2 AML, 1 ALL), 1 AML and 1 ALL are
well and without relapse to date, 5 and 6
years respectively after diagnosis. This
finding maywarrantfurther study.
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